IMUX Insider Trading
Insider Ownership Percentage: 3.00%
Insider Buying (Last 12 Months): $100,395.00
Insider Selling (Last 12 Months): $0.00
Immunic Share Price & Price History
Current Price: $1.20
Price Change: ▼ Price Decrease of -0.04 (-3.23%)
As of 03/28/2025 05:00 PM ET
Immunic Insider Trading History
Immunic Institutional Trading History
Data available starting January 2016
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Read More on Immunic
Volume
653,857 shs
Average Volume
604,174 shs
Market Capitalization
$108.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.89
Who are the company insiders with the largest holdings of Immunic?
Who are the major institutional investors of Immunic?
Immunic's top institutional shareholders include:
- Janus Henderson Group PLC — 2.99%
- Focus Partners Wealth — 2.41%
- Adage Capital Partners GP L.L.C. — 1.55%
- 683 Capital Management LLC — 0.78%
- Millennium Management LLC — 0.64%
- Renaissance Technologies LLC — 0.63%
Learn More about top institutional investors of Immunic stock.
Which institutional investors are selling Immunic stock?
During the last quarter, IMUX stock was sold by these institutional investors:
- Adage Capital Partners GP L.L.C.
- Janus Henderson Group PLC
- Two Sigma Investments LP
- Marshall Wace LLP
- Jane Street Group LLC
Which institutional investors are buying Immunic stock?
During the previous quarter, IMUX stock was purchased by institutional investors including:
- Millennium Management LLC
- Renaissance Technologies LLC
- OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC
- Barclays PLC
- HB Wealth Management LLC
- Citadel Advisors LLC
- Invesco Ltd.
- Focus Partners Wealth
In the last year, these company insiders have bought Immunic stock:
- Richard Alan Rudick (Director)
- Glenn Whaley (CFO)
Learn More investors buying Immunic stock.